Skip to main content

Advertisement

SpringerLink
Log in

Letter to the editor

  • Urology - Letter to the Editor
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Jian Z, Yuan C, Li H et al (2020) Vibegron 50 mg is the optimal algorithm in the pharmacologic management of overactive bladder : outcomes from a systematic review and meta—analysis. Int Urol Nephrol 52:2215–2221. https://doi.org/10.1007/s11255-020-02536-5

    Article  PubMed  Google Scholar 

  2. Yoshida M, Takeda M, Gotoh M et al (2018) Vibegron, a novel potent and selective b3 -adrenoreceptor agonist, for the treatment of patients with overactive bladder. Eur Urol 73(5):783–790. https://doi.org/10.1016/j.eururo.2017.12.022

    Article  CAS  PubMed  Google Scholar 

  3. Staskin D, Frankel J, Varano S et al (2020) International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol 204(2):316–324. https://doi.org/10.1097/JU.0000000000000807

    Article  PubMed  Google Scholar 

  4. Mitcheson HD, Samanta S, Muldowney K et al (2018) Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase iib, randomized, double-blind. Control Trial Eur Urol 75(2):274–282. https://doi.org/10.1016/j.eururo.2018.10.006

    Article  CAS  Google Scholar 

  5. Yoshida M, Kakizaki H, Takahashi S et al (2018) Long-term safety and efficacy of the novel b3 -adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: a phase III prospective study. Int J Urol 25(7):668–675. https://doi.org/10.1111/iju.13596

    Article  CAS  PubMed  Google Scholar 

  6. Urovant Sciences (2020) GEMTESA (vibegron) tablets, for oral use [1-14]. U.S. Food and Drug Administration Website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213006s000lbl.pdf. Accessed 05 Jan 2021

Download references

Author information

Authors and Affiliations

  1. Center for Drug of Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    Fengli Wang & Lujin Li

Authors
  1. Fengli Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lujin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lujin Li.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, F., Li, L. Letter to the editor. Int Urol Nephrol 53, 2063–2064 (2021). https://doi.org/10.1007/s11255-021-02898-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-021-02898-4

Search

Navigation